EVQLV
Techstars '20Woodside, US · 8 known investors
EVQLV develops a computational platform for antibody discovery that uses machine learning and computational biology to accelerate and reduce the cost of generating fully-human antibodies for drug development. The platform serves pharmaceutical and biotech partners working on antibody therapeutics.
Investors · 8
In the news
- AI, meet antibodies. Inside EVQLV’s 'ChatGPT moment for biology' - Refresh Miamirefreshmiami.com · 2025
- eMerge win will fuel EVQLV’s growth toward building a future of personalized medicine - Refresh Miamirefreshmiami.com · 2024
- Hatter Angel Network Invests to Accelerate Growth in Biotechnology - Stetson Todaywww2.stetson.edu · 2023
- Stetson students partner with biotech company to obtain $135,000 in funding | Observer Local News | Palm Coast Observer and Ormond Beach Observerobserverlocalnews.com · 2023
- Life sciences startup EVQLV is leveraging AI to sell antibody sequences - Refresh Miamirefreshmiami.com · 2023